文献一覧: Kohei Kaku (著者)

9 0 0 0 OA Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ―

著者: Kohei Kaku Jisoo Lee Michaela Mattheus Stefan Kaspers Jyothis George Hans-Juergen Woerle on behalf of the EMPA-REG OUTCOME® Investigators
出版者: 日本循環器学会
雑誌: Circulation Journal (ISSN:13469843)
巻号頁・発行日: pp.CJ-16-1148, (Released:2016-12-23)
参考文献数: 16
被引用文献数: 1 106

Background:In the EMPA-REG OUTCOME®trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race.Methods and Results:Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48–0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population.Conclusions:Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

2016-12-24 20:56:38
9 + 9 Twitter

3 0 0 0 OA Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ―

著者: Kohei Kaku Jisoo Lee Michaela Mattheus Stefan Kaspers Jyothis George Hans-Juergen Woerle on behalf of the EMPA-REG OUTCOME® Investigators
出版者: 日本循環器学会
雑誌: Circulation Journal (ISSN:13469843)
巻号頁・発行日: vol.81, no.2, pp.227-234, 2017-01-25 (Released:2017-01-25)
参考文献数: 16
被引用文献数: 1 106

2019-03-23 11:37:08
3 + 0 Twitter

2 0 0 0 OA Hypoglycemic Coma Induced by the Use of Succinic Acid Cibenzoline in Frail Late-stage Elderly Subjects

著者: Yurie Hirata Shinji Kamei Fuminori Tatsumi Masashi Shimoda Akihito Tanabe Junpei Sanada Yoshiro Fushimi Shintaro Irie Tomoatsu Mune Kohei Kaku Hideaki Kaneto
出版者: 一般社団法人日本内科学会
雑誌: Internal Medicine (ISSN:09182918)
巻号頁・発行日: vol.56, no.12, pp.1527-1529, 2017-06-15 (Released:2017-06-15)
参考文献数: 11
被引用文献数: 1

Succinic acid cibenzoline (CZ) is an antiarrhythmic agent often used for the treatment of tachyarrhythmia. However, hypoglycemia should be avoided in the treatment of diabetes. We herein report two late-stage elderly subjects who experienced a severe and prolonged hypoglycemic coma after the usage of CZ. These cases suggest that, when CZ is administered to elderly subjects with renal dysfunction and/or frailty, we should be aware of the possibility that this medicine may induce hypoglycemia and should adjust the dose as appropriate and monitor the concentration of CZ to avoid severe hypoglycemia.

2017-06-16 06:44:10
2 + 1 Twitter

1 0 0 0 OA Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

著者: Yutaka Seino Kohei Kaku Nobuya Inagaki Masakazu Haneda Takashi Sasaki Atsushi Fukatsu Michito Ubukata Soichi Sakai Yoshishige Samukawa
出版者: The Japan Endocrine Society
雑誌: Endocrine Journal (ISSN:09188959)
巻号頁・発行日: vol.62, no.7, pp.593-603, 2015 (Released:2015-07-31)
参考文献数: 20
被引用文献数: 13 23

Luseogliflozin, a selective sodium glucose cotransporter 2 inhibitor, was demonstrated in a previous 24-week study of type 2 diabetic patients to be efficacious and well tolerated. This study mainly aimed to evaluate the long-term safety of luseogliflozin monotherapy in Japanese type 2 diabetic patients based on the Japanese guidelines. Additionally, long-term efficacy was also evaluated. Patients on diet and exercise therapy alone with an HbA1c of 6.9-10.5% received luseogliflozin 2.5 mg once daily for 52 weeks. For patients with insufficient glycemic control, this dose was able to be increased to 5 mg at Week 24. Adverse events (AEs), clinical laboratory tests, vital signs and 12-lead electrocardiograms were used to assess safety. Efficacy endpoints consisted of changes in HbA1c, fasting plasma glucose (FPG), and body weight from baseline. Of 299 patients who received luseogliflozin, 279 completed the study. Most AEs were mild in severity with incidences of AEs and adverse drug reactions at 75.3% and 16.7%, respectively. Although hypoglycemia was observed in 7 patients (2.3%), no major hypoglycemic episodes occurred. The incidences of AEs of special interest, including pollakiuria, volume depletion and urinary tract/genital infections, were at acceptable levels. Luseogliflozin significantly lowered HbA1c (-0.50%, P< 0.001), FPG (-16.3 mg/dL, P< 0.001) and body weight (-2.68 kg, P< 0.001) at Week 52 compared to baseline. Up-titration to 5 mg further improved glycemic control. In this long-term study of Japanese type 2 diabetic patients, luseogliflozin monotherapy was well tolerated for 52 weeks and provided a sustained glycemic lowering effect and reduced body weight.

2019-07-21 19:50:36
1 + 0 Twitter